Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma

Background CD4+ T-cell lymphocytopenia and immune dysfunction are factors that drive the onset and persistence of Kaposi sarcoma (KS) in people with (PWH) and without HIV. Standard chemotherapy agents for KS can contribute to increasing CD4+ T cell lymphocytopenia. IL-7 is a cytokine that is essenti...

Полное описание

Библиографические подробности

Главные авторы:	Leonard D’Amico, Martin Cheever, Steven P Fling, Anna Wright, Kathryn Lurain, Ramya Ramaswami, Irene Ekwede, Thomas S Uldrick, Robert Yarchoan, Judith C Kaiser, Angela Shaulov Kask, Manoj P Menon, Paul Couey, Eli Burnham, Allysson Angeldekao, Byung Ha Lee, Li-Lian Kwok, Chia-Ching Jackie Wang
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMJ Publishing Group 2025-02-01
Серии:	Journal for ImmunoTherapy of Cancer
Online-ссылка:	https://jitc.bmj.com/content/13/2/e010291.full
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!